Simcere Pharmaceutical Group Limited (2096.HK) Comparison with companies in other sectors?

Simcere Pharmaceutical Group Limited has a share price of 2.47B. You can analyze Simcere Pharmaceutical Group Limited (2096.HK) competitors across different market sectors through stock heatmaps.

What are 2096.HK's NET and operating margins?

Simcere Pharmaceutical Group Limited (2096.HK) operating margin is around 0.13, and net profit margin is approximately 0.11 as of the latest reports.

In what way does 2096.HK's earnings per share (EPS) trend reflect its financial momentum?

Simcere Pharmaceutical Group Limited (2096.HK) EPS is 0.32 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Simcere Pharmaceutical Group Limited is 39.06, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Simcere Pharmaceutical Group Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Simcere Pharmaceutical Group Limited like P/E which is 39.69, P/B which is 4.12, and PEG which is 0.08. Compare them with sector averages to evaluate if the stock is priced fairly.

Simcere Pharmaceutical Group Limited

2096.HK•HKSE

Healthcare

Biotechnology

HK$12.28

HK$-0.96(-7.25%)

Simcere Pharmaceutical Group Limited (2096.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.32

P/E Ratio

39.06

ROE

0.10%

Net Margin

0.11%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$30.93B

Shares OutstandingTotal number of shares issued

$2.47B

Book Value/ShareNet worth per share

$2.79

Revenue/ShareAnnual revenue per share

$2.62

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.32

Net MarginNet income as percentage of revenue

11.05%

Operating MarginOperating income as percentage of revenue

12.78%

ROEReturn on shareholders' equity

10.49%

ROAReturn on total assets

6.37%

ROCEReturn on capital employed

9.66%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.34

Cash/ShareCash and equivalents per share

$0.77

FCF YieldFree cash flow as percentage of market cap

3.04%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.16

Dividend YieldAnnual dividend as percentage of stock price

1.40%

Financial Ratios Analysis data is not available for 2096.HKFinancial Ratios Analysis details for 2096.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2096.HKSector Benchmarking details for 2096.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Simcere Pharmaceutical Group Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Simcere Pharmaceutical Group Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Simcere Pharmaceutical Group Limited's unique business strengths and challenges.

Key Financial Metrics for Simcere Pharmaceutical Group Limited

For Simcere Pharmaceutical Group Limited, essential financial indicators include EPS 0.32, PE 39.06, and ROE 0.10. These key ratios reveal insights into Simcere Pharmaceutical Group Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Simcere Pharmaceutical Group Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Simcere Pharmaceutical Group Limited

Metrics like Net Margin 11.05% and ROA 6.37% shed light on how well Simcere Pharmaceutical Group Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Simcere Pharmaceutical Group Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Simcere Pharmaceutical Group Limited

Using ratios such as P/B Ratio 4.12 and PEG Ratio 0.08, investors can assess whether Simcere Pharmaceutical Group Limited is appropriately valued based on its financials and growth potential. These figures, combined with Simcere Pharmaceutical Group Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Simcere Pharmaceutical Group Limited

Financial health indicators, such as Debt/Equity Ratio 0.17 and Cash Flow $0.34, provide a snapshot of Simcere Pharmaceutical Group Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Simcere Pharmaceutical Group Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Simcere Pharmaceutical Group Limited

Investing in Simcere Pharmaceutical Group Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Simcere Pharmaceutical Group Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;